Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality - Results of prospective analysis for the Atherosclerosis Risk in Communities study

Journal of Internal Medicine

Volumn 262, Issue 1, 2007, Pages 113-122

  Hong, Y ^a   Jin, X ^a,c   Mo, J ^b   Lin, H M ^a   Duan, Y ^a   Pu, M ^a,d   Wolbrette, D L ^a   Liao, D ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c Shanghai Institute of Cardiovascular Diseases   (China)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular risk factors; Cohort study; Coronary heart disease; Metabolic syndrome; Mortality; Obesity

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CAUCASIAN; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; COMMUNITY ASSESSMENT; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; ELECTROCARDIOGRAPHY MONITORING; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL PATIENT; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEGRO; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SILENT MYOCARDIAL INFARCTION; STATISTICAL ANALYSIS; TREND STUDY; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 34347255382     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2007.01781.x     Document Type: Article

References (54)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP). JAMA 2001 285 : 2486 97.
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 : 3143 421.
3. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and Management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive Summary. Circulation 2005 112 : 2735 52.
4. Hong Y, Pedersen NL, Brismar K, de Faire U. Genetic and environmental architecture of the features of the insulin-resistance syndrome. Am J Hum Genet 1997 60 : 143 52.
5. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 : 1837 47.
6. Grundy SM, Pasternak R, Greenland P, Smith S Jr., Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999 100 : 1481 92.
7. Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss. An update of the 1997 American Heart Association Scientific Statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006 113 : 898 918.
8. Graham IM. Guidelines on cardiovascular disease prevention in clinical practice: the European perspective. Curr Opin Cardiol 2005 20 : 430 9.
9. Eckel RH, Grundy SM, Zimmet PZ. The Metabolic Syndrome. Lancet 2005 365 : 1415 28.
10. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998 15 : 539 53.
11. International Diabetes federation. Worldwide definition of the metabolic syndrome. 2006. Available at: http://www.idf.org/webdata/docs/IDF_Meta- syndrome_definition.pdf. Access October 27, 2006.
12. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004 33 : 351 75.
13. Ford ES. Prevalence of the metabolic syndrome in US populations. Endocrinol Metab Clin North Am 2004 33 : 333 50.
14. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes 1998 22 : 39 47.
15. Ogden CL, Johnson CL, Carroll MD et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006 295 : 1549 55.
16. Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006 113 : e85 e151.
17. Silventoinen K, Sans S, Tolonen H et al. WHO MONICA Project. Trends in obesity and energy supply in the WHO MONICA Project. Int J Obes 2004 28 : 710 8.
18. Balkau B, Charles MA. Comments on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999 16 : 442 3.
19. Einhorn D, Reaven GM, Cobin RH et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003 9 : 237 52.
20. Isomaa B, Almgren P, Tuomi T et al. cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001 24 : 683 9.
21. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002 288 : 2709 16.
22. Resnick HE, Jones K, Ruotolo G et al. Strong Heart Study. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 2003 26 : 861 7.
23. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003 108 : 414 9.
24. Bonora E, Kiechl S, Willeit J et al. Bruneck study. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 2003 26 : 1251 7.
25. Girman CJ, Rhodes T, Mercuri M et al. 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004 93 : 136 41.
26. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnson K, Pyorala K, for the DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004 164 : 1066 76.
27. Bonora E, Targher G, Formentini G et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004 21 : 52 58.
28. Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004 110 : 1245 50.
29. Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FL SMART Study Group. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004 25 : 342 8.
30. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004 173 : 307 12.
31. McNeill AM, Rosamond WD, Girman CJ et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005 28 : 385 90.
32. Turhan H, Yasar AS, Basar N, Bicer A, Erbay AR, Yetkin E. High prevalence of metabolic syndrome among young women with premature coronary artery disease. Coron Artery Dis 2005 16 : 37 40.
33. Dekker JM, Girman C, Rhodes T et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005 112 : 666 73.
34. ARIC investigators. The atherosclerosis risk in the communities (ARIC) study: Design and objectives. Am J Epidemiol 1989 129 : 687 702.
35. White AD, Folsom AR, Chambless LE et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol 1996 49 : 223 33.
36. Rosamond WD, Chambless LE, Folsom AR et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998 339 : 861 7.
37. Rosamond WD, Folsom AR, Chambless LE, Wang CH, ARIC Investigators. Coronary heart disease trends in four United States communities. The Atherosclerosis Risk in Communities (ARIC) study 1987-1996. Int J Epidemiol 2001 30 (Suppl. 1 0S17 S22.
38. Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC hemostasis study, I: development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 1989 61 : 15 19.
39. Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983 29 : 1075 80.
40. Nagele U, Hagele EO, Sauer G et al. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Biochem 1984 22 : 165 74.
41. Warnick GR, Mayfield C, Benderson J, Chen JS, Albers JJ. HDL cholesterol quantitation by phosphotungstate-Mg2+ and by dextran sulfate-Mn2+-polyethylene glycol precipitation, both with enzymic cholesterol assay compared with the lipid research method. Am J Clin Pathol 1982 78 : 718 23.
42. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 18 : 499 502.
43. Harris MM, Stevens J, Thomas N, Schreiner P, Folsom AR. Associations of fat distribution and obesity with hypertension in a bi-ethnic population: the ARIC study. Atherosclerosis Risk in Communities Study. Obes Res 2000 8 : 516 24.
44. Schreiner PJ, Terry JG, Evans GW, Hinson WH, Crouse JR III., Heiss G. Sex-specific associations of magnetic resonance imaging-derived intra-abdominal and subcutaneous fat areas with conventional anthropometric indices. The Atherosclerosis Risk in Communities Study. Am J Epidemiol 1996 144 : 335 45.
45. National Heart Lung and Blood Institute. ARIC Manuals of Operation: No. 1, General Description and Study Management; No. 2, Cohort Component Procedures; No. 3, Surveillance Component Procedures; No. 4, Pulmonary Function Assessment; No. 5, Electrocardiography; No. 6, Ultrasound Assessment; No. 7, Blood Collection and Processing; No. 8, Lipid and Lipoprotein Determinations; No. 9, Hemostasis Determinations; No. 10, Clinical Chemistry Determinations; No. 11, Sitting Blood Pressure and Postural Changes in Blood Pressure and Heart Rate; No. 12, Quality Assurance. Chapel Hill, NC : ARIC Coordinating Center, School of Public Health, University of North Carolina, 1987.
46. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002 287 : 356 9.
47. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr., Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004 110 : 380 5.
48. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Diabetes Care 2005 28 : 2289 304.
49. Wilson PWF, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005 112 : 3066 72.
50. Goldstein LB, Adams R, Alberts MJ et al. AHA/ASA Guidelines. Primary Prevention of Ischemic Stroke. A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2006 113 : e873 923.
51. Smith SC Jr., Allen J, Blair SN et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Circulation 2006 113 : 2363 72.
52. Pearson TA, Blair SN, Daniels SR et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002 106 : 388 91.
53. Wong ND, Pio JR, Franklin SS, L'Italien GJ, Kamath TV, Williams GR. Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am J Cardiol 2003 91 : 1421 6.
54. Gotto AM Jr., Blackburn GL, Dailey GE III. et al. The metabolic syndrome: a call to action. Coron Artery Dis 2006 17 : 77 80.